OakChart

InflaRx NV

IFRXHealthcare·Biotechnology·Germany·Micro·NASD·Nov 11 • 3:59 PM ET

1.18-0.03 (-2.48%)
2026-11-12 02:20 CET
Market cap
178.32 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-2.81 USD m
Free cash flow, TTM
-4.58 USD m
EPS diluted, TTM
-0.02
P/E
-
Compare

Price

IFRX against its 20, 50 and 200-day averages
2050200miss
1.502.002.503.003.7M7.5MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26IFRXclose 1.1820-day 1.5050-day 1.74200-day 1.651.1852w high

60.0% under the 52-week high of 2.95 on 7 May 2026. 52-week low 0.80 on 5 Feb 2026. Last 15 sessions, 53.0% high to low

Volume 0.68× normal · the line is the 50-bar volume average

Profile

IFRX
52-week range, 18% of the way up
0.802.95

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. The company was founded by Niels Christoph Riedemann, Renfeng Guo, and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.

Employees65
IPONov 08, 2017
Beta2.46
ATR, 14d0.15
Rel volume0.68
Short float10.22%
Insider own14.75%
Inst own59.89%

Snapshot

6 groups

Valuation

Index-
Market Cap173.90M
Enterprise Value43.74M
Income-
Sales-
Book/sh1.11
Cash/sh0.89
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees65
IPONov 08, 2017

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B1.06
P/C1.33
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio7.26
Current Ratio7.26
Debt/Eq0.01
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-
EPS next Y-0.35
EPS next Q-0.05
EPS this Y66.28%
EPS next Y-38.36%
EPS next 5Y16.54%
EPS past 3/5Y-2.98% 11.77%
Sales past 3/5Y- -
EPS Y/Y TTM-40.62%
Sales Y/Y TTM-
EPS Q/Q92.08%
Sales Q/Q-100.00%
EarningsNov 03 BMO
EPS/Sales Surpr.64.16% -

Ownership

Insider Own14.75%
Insider Trans0.00%
Inst Own59.89%
Inst Trans52.83%
ROA-
ROE-
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-21.22%
SMA50-32.09%
SMA200-28.62%
Trades-

Technical

Shs Outstand147.37M
Shs Float125.63M
Short Float10.22%
Short Ratio15.12
Short Interest12.84M
52W High2.95 -59.99%
52W Low0.80 47.80%
Volatility12.43% 10.22%
ATR (14)0.15
RSI (14)29.07
Beta2.46
Rel Volume0.68
Avg Volume849.79K
Volume577,525

Performance

Perf Week-20.27%
Perf Month-23.87%
Perf Quarter-41.29%
Perf Half Y-53.17%
Perf YTD16.83%
Perf Year-28.48%
Perf 3Y-7.81%
Perf 5Y-75.97%
Perf 10Y-
Recom1.00
Target Price8.45
Prev Close1.21
Price1.18
Change %-2.48%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Sep 14, 2026InitiatedNNeedhamBuy$8+578.0%
May 13, 2026UpgradeRRaymond JamesOutperform → Strong Buy$9+662.7%
Apr 24, 2026ResumedOOppenheimerOutperform$7 → $5+323.7%
Dec 03, 2025DowngradeLLeerink PartnersOutperform → Market Perform$2+69.5%
Sep 02, 2025ResumedHH.C. WainwrightBuy$6+408.5%
May 29, 2025DowngradeRRaymond JamesStrong Buy → Outperform$2+69.5%
Apr 29, 2025InitiatedCCantor FitzgeraldOverweight$10+747.5%
Apr 05, 2023UpgradeGGuggenheimNeutral → Buy$8+578.0%
Feb 28, 2022DowngradeGGuggenheimBuy → Neutral
Oct 28, 2021UpgradeRRaymond JamesOutperform → Strong Buy$10 → $14+1,086.4%

Peers

Mkt cap
TickerCompanyMkt cap
ANNXAnnexon Inc794.34M
OMEROmeros Corp1.31B
EVMNEvommune Inc312.84M
AKTXAkari Therapeutics Plc ADR13.04M
DNTHDianthus Therapeutics Inc5.03B
UPBUpstream Bio Inc175.27M
ZURAZura Bio Ltd137.75M
ACRSAclaris Therapeutics Inc688.38M
IMUXImmunic Inc110.79M
ALMSAlumis Inc883.74M

Held by

AUM
TickerCompanyAUM
GWXState Street SPDR S&P International Small Cap ETFAUM: 906.57M
QQQSInvesco NASDAQ Future Gen 200 ETFAUM: 20.53M

News

latest 14 of 200
  • InflaRx Announces Publication of Phase 1 Data Demonstrating Favorable Safety and Pharmacokinetic/Pharmacodynamic Profile of Izicopan (GlobeNewswire)
  • InflaRx Highlights Izicopan Development Path and Commercial Opportunity in ANCA-Associated Vasculitis at Capital Markets Day (GlobeNewswire) -8.22%
  • InflaRx Announces November Investor Events (GlobeNewswire) +5.40%
  • InflaRx Highlights Izicopan's Therapeutic Potential at Kidney Week 2026 (GlobeNewswire)
  • InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026 (GlobeNewswire)
  • InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development (GlobeNewswire)
  • InflaRx to Host Virtual Capital Markets Day (GlobeNewswire)
  • InflaRx Announces Participation in September Investor Conferences (GlobeNewswire)
  • InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones (GlobeNewswire)
  • InflaRx to Report Second Quarter 2026 Results on August 6, 2026 (GlobeNewswire)
  • InflaRx Assessing Feasibility of Broadened Strategy for ANCA-Associated Vasculitis in Europe Following EMA Recommendation on Tavneos (GlobeNewswire)
  • InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares (GlobeNewswire)
  • InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares (GlobeNewswire) +26.90%
  • InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-03-0.022-0.063-0.1010.000.007
2026Q22026-08-06-0.104-0.066-0.1050.000.016
2026Q12026-05-07-0.091-0.139-0.0910.000.016
2025Q42026-03-19-0.179-0.172-0.183-0.020.035
2025Q32025-10-30-0.212-0.176-0.2120.100.087
2025Q22025-08-07-0.245-0.247-0.2410.050.051
2025Q12025-05-07-0.147-0.209-0.1380.000.175
2024Q42025-03-20-0.102-0.255-0.0980.000.125
2024Q32024-11-08-0.324-0.270-0.3260.130.094
2024Q22024-08-08-0.262-0.215-0.2530.010.074
2024Q12024-05-08-0.183-0.243-0.1780.041.394
2023Q42024-03-21-0.285-0.198-0.2910.001.394
2023Q32023-11-01-0.138-0.252-0.1380.062.544
2023Q22023-08-10-0.154-0.347-0.1571.730.004
2023Q12023-05-11-0.274-0.295-0.2662.830.244
2022Q42023-03-22-0.169-0.272-0.1850.000.004

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-2.166-2.213-2.2920.050.00
2020FY-1.484-1.314-1.4310.040.04
2021FY-1.211-1.151-1.2960.004.73
2022FY-0.693-0.866-0.7010.000.00
2023FY-0.836-0.746-0.8403.564.87
2024FY-0.906-0.965-0.8460.220.23
2025FY-0.776-0.800-0.7900.010.08
2026FY--0.254--0.00
2027FY--0.352--0.00
2028FY--0.438--0.00
2029FY--0.540--150.68
2030FY--0.642--5.32

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-034000.000.000.00
2026Q4S2026-10-234000.000.000.00
2026Q4S2026-10-205000.000.000.00
2026Q4S2026-09-115010.000.000.00
2026Q4S2026-08-064010.000.000.00
2026Q4S2026-08-014000.010.000.02
2026Q4S2026-07-225000.010.000.02
2026Q4S2026-06-025010.010.000.02
2026Q4S2026-05-085020.010.000.02
2026Q4S2026-05-075010.010.000.02
2026Q4S2026-03-235010.010.000.02
2026Q4S2026-03-194010.010.000.02
2026Q4S2026-02-182000.010.000.02
2026Q4S2026-02-153000.840.002.48

Estimate history

EPS, annual-2.933-1.402-2.292-1.431-1.296-0.701-0.84-0.846-0.765
Period201720182019202020212022202320242025
EPS, quarterly-0.178-0.253-0.326-0.138-0.241-0.212-0.091-0.105-0.019
PeriodQ1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25Q1 '26Q2 '26Q3 '26
Sales, annual0000000.0680.1790.033
Period201720182019202020212022202320242025
Sales, quarterly0.0390.0070.13600.0450.028000
PeriodQ1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25Q1 '26Q2 '26Q3 '26
Shares, annual7.06825.96426.10528.22844.20444.70458.88359.35272.293147.368
Period201720182019202020212022202320242025MRQ
Shares, quarterly58.88358.88358.88367.74767.74767.74772.293147.368147.368
PeriodQ1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.030.180.070.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.108.644.081.120.630.790.810.740.21
Gross Profit-0.10-8.61-3.90-1.06-0.63-0.79-0.81-0.74-0.21
Selling, General and Administrative Excl. Other6.5848.8559.1661.7854.4455.5738.1263.1544.41
Research and Development3.4929.0338.2544.3539.3742.0529.1049.7229.32
Other Operating Expense--0.000.00---0.00-
Operating Income-6.68-57.46-63.06-62.84-55.07-56.36-38.93-63.89-44.61
Interest Expense0.020.040.020.040.050.030.030.020.00
Unusual Expense-3.00-6.41--14.22-21.14-9.810.00--
Net Income Before Taxes-2.81-51.49-49.82-46.13-30.99-53.93-38.74-59.61-35.17
Income Taxes0.000.010.010.000.000.000.000.000.00
Consolidated Net Income-2.81-51.50-49.83-46.13-30.99-53.93-38.74-59.61-35.17
Net Income From Continuing Operations-2.81-51.50-49.83-46.13-30.99-53.93-38.74-59.61-35.17
Net Income-2.81-51.50-49.83-46.13-30.99-53.93-38.74-59.61-35.17
EPS (Recurring)-0.03-0.83-0.85-1.02-1.04-1.46-1.43-2.29-1.40
EPS (Basic, Before Extraordinaries)-0.02-0.77-0.85-0.84-0.70-1.30-1.43-2.29-1.40
EPS (Diluted)-0.02-0.77-0.85-0.84-0.70-1.30-1.43-2.29-1.40
EBITDA-6.58-56.99-62.53-62.22-54.44-55.57-38.12-63.15-44.41
Non-Operating Income (Expense)0.89-0.4013.262.532.98-7.360.224.319.44
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.303.573.133.696.355.121.275.3514.26
Price To Sales Ratio-2,053.06811.521,312.96-----
Gross Margin--26,015.74-2,175.51-1,548.72-----
Operating Margin--173,593.34-35,162.96-92,128.48-----
Net Margin--155,583.58-27,785.02-67,630.20-----
Shares Outstanding147.3772.2959.3558.8844.7044.2028.2326.1125.96
Market Capitalization178.32178.32145.4495.98137.03210.33131.31103.38943.33

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q32025Q22025Q12024Q32024Q2
Total Revenue0.000.000.000.030.040.000.140.01
Cost of Goods Sold Incl. D&A0.100.110.100.122.720.120.040.37
Gross Profit-0.10-0.11-0.10-0.09-2.68-0.120.09-0.37
Selling, General and Administrative Excl. Other6.588.407.9211.6013.0314.1417.0816.23
Research and Development3.495.514.417.298.167.3812.2410.78
Other Operating Expense----0.000.000.000.00
Operating Income-6.68-8.51-8.02-11.69-15.71-14.26-16.98-16.59
Interest Expense0.020.020.020.020.000.000.010.01
Unusual Expense-3.009.20-0.243.71-0.97-6.430.000.00
Net Income Before Taxes-2.81-12.38-6.54-14.31-16.34-8.75-19.16-14.91
Income Taxes0.000.000.000.010.000.000.010.00
Consolidated Net Income-2.81-12.38-6.54-14.33-16.34-8.75-19.17-14.91
Net Income From Continuing Operations-2.81-12.38-6.54-14.33-16.34-8.75-19.17-14.91
Net Income-2.81-12.38-6.54-14.33-16.34-8.75-19.17-14.91
EPS (Recurring)-0.03-0.05-0.09-0.17-0.25-0.21-0.33-0.25
EPS (Basic, Before Extraordinaries)-0.02-0.11-0.09-0.21-0.24-0.14-0.33-0.25
EPS (Diluted)-0.02-0.11-0.09-0.21-0.24-0.14-0.33-0.25
EBITDA-6.58-8.40-7.92-11.58-15.57-14.14-16.86-16.44
Non-Operating Income (Expense)0.895.341.261.11-1.60-0.92-2.171.70
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.300.691.100.500.901.860.51-
Price To Sales Ratio------488.47894.34
Gross Margin----320.17-5,985.41-68.59-5,376.59
Operating Margin----41,988.40-35,139.01--12,486.39-242,459.12
Net Margin----51,453.01-36,560.07--14,092.85-217,799.31
Shares Outstanding147.37147.3772.2967.7567.7567.7558.8858.88
Market Capitalization178.32329.9464.6689.9653.0468.4890.09102.46

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments54.5654.7199.7286.5394.8699.27129.63178.98148.04
Short Term Receivables1.681.804.294.251.461.740.000.000.14
Inventories0.007.1412.560.000.000.000.000.000.00
Other Current Assets6.7510.554.3613.1812.494.573.931.820.69
Total Current Assets62.9974.20120.92103.96108.80105.57133.56180.80148.87
Net Property, Plant & Equipment1.351.051.501.751.911.171.590.710.21
Total Investments and Advances0.283.2010.003.1030.940.330.310.240.02
Intangible Assets0.050.050.080.150.270.430.510.250.05
Other Assets0.180.210.280.330.380.430.510.000.00
Total Assets64.8578.72132.79109.29142.31107.94136.47182.01149.15
Short Term Debt Incl. Current Port. of LT Debt0.300.420.410.390.420.410.580.000.00
Accounts Payable1.143.535.640.000.000.000.007.61-
Income Tax Payable--------0.00
Other Current Liabilities13.8010.7112.5613.5120.9111.9415.201.265.72
Total Current Liabilities15.2514.6718.6113.9021.3312.3615.788.875.72
Long Term Debt0.750.410.821.051.210.270.370.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.070.00
Other Liabilities0.040.040.040.040.040.040.040.000.02
Total Liabilities16.0415.1219.4715.0022.5812.6716.208.935.74
Non-Equity Reserves0.000.000.000.000.000.000.000.010.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity48.8163.60113.3294.29119.7395.27120.27173.06143.41
Total Shareholders Equity48.8163.60113.3294.29119.7395.27120.27173.06143.41
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity48.8163.60113.3294.29119.7395.27120.27173.06143.41
Total Liabilities & Stockholders Equity64.8578.72132.79109.29142.31107.94136.47182.01149.15
Book Value Per Share0.681.071.922.112.713.374.616.6720.29
Tangible Book Value Per Share0.671.071.922.112.703.364.596.6620.28
Full-Time Employees657466485949453821
Price to Book Ratio1.092.000.771.411.761.490.865.46-3.47
Return on Assets-71.75-47.12-38.11-24.63-43.10-31.70-37.43-21.24-30.33
Return on Equity-91.64-56.33-44.44-28.96-50.17-35.95-40.64-22.23-47.01
Return on Invested Capital-103.92-77.84-40.41-32.50-44.60-40.55-49.41-20.32-19.06
Quick Ratio4.134.575.827.485.108.548.4620.3926.01
Current Ratio4.135.066.507.485.108.548.4620.3926.01

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-2.61-51.50-49.83-46.13-30.99-53.93-38.74-59.61-35.17
Depreciation0.100.470.520.610.630.790.810.740.21
Other Funds (Non Cash)-2.475.69-0.763.555.174.122.386.712.85
Funds from Operations-4.98-45.34-50.06-41.97-25.19-49.02-35.55-52.16-32.12
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital0.465.48-2.461.08-10.271.82-6.093.804.14
Income Taxes Payable--------0.23-
Cash from Operating Activities-4.52-39.85-52.52-40.88-35.46-47.20-41.64-48.36-27.97
Capital Expenditures-0.06-0.13-0.05-0.09-0.17-0.04-0.11-0.67-0.95
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments-70.113.7856.69-19.0420.52-30.6324.4623.43-116.38
Purchase of Investments-83.33-52.03-38.23-112.49-67.76-115.26-115.82-92.48-125.83
Sale Or Maturity of Investments13.2255.8194.9293.4588.2884.63140.28115.919.45
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-70.173.6556.64-19.1320.34-30.6724.3522.77-117.33
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.000.000.000.00
Change in Capital Stock-1.4638.000.8457.692.4273.2110.870.0058.57
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock-1.4638.000.8457.692.4273.2110.870.0058.57
Proceedsfrom Stock Options-1.4523.430.8457.432.4272.0110.310.0058.57
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.00-0.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities-1.5337.600.4257.282.0472.7810.46-0.3358.57
Exchange Rate Effect-0.41-4.051.53-1.052.595.43-1.331.016.64
Net Change in Cash-76.63-2.666.07-3.78-10.490.33-8.17-24.91-80.10
Free Cash Flow-4.58-39.99-52.55-40.94-35.63-47.25-41.72-49.02-28.93
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q32025Q22025Q1
Cash & Short Term Investments131.08181.2345.8652.4656.3471.14
Short Term Receivables1.281.771.902.312.061.83
Inventories0.000.000.005.965.917.45
Other Current Assets5.066.096.8513.8513.3612.06
Total Current Assets137.42189.1054.6174.5777.6892.48
Net Property, Plant & Equipment1.181.221.231.460.950.98
Total Investments and Advances44.360.270.270.287.320.26
Intangible Assets0.140.090.050.050.060.06
Other Assets0.130.140.160.190.210.21
Total Assets183.23190.8356.3376.5686.2193.98
Short Term Debt Incl. Current Port. of LT Debt0.330.310.290.320.460.44
Accounts Payable0.390.950.422.462.331.53
Other Current Liabilities18.2021.7512.4119.6116.1715.53
Total Current Liabilities18.9223.0113.1222.3918.9717.50
Long Term Debt0.590.640.660.820.240.32
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.040.040.040.040.040.04
Total Liabilities19.5523.6913.8323.2519.2517.86
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity163.68167.1342.5053.3166.9676.12
Total Shareholders Equity163.68167.1342.5053.3166.9676.12
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity163.68167.1342.5053.3166.9676.12
Total Liabilities & Stockholders Equity183.23190.8356.3376.5686.2193.98
Book Value Per Share1.111.130.590.790.991.12
Tangible Book Value Per Share1.111.130.590.790.991.12
Price to Book Ratio1.093.811.141.360.700.82
Return on Invested Capital-1.71-7.38-15.16-26.47-24.32-11.45
Quick Ratio7.268.224.163.063.784.86
Current Ratio7.268.224.163.334.105.28

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q32025Q22025Q1
Net Income-2.61-12.34-6.54-15.13-17.01-8.75
Depreciation0.100.110.100.120.140.12
Other Funds (Non Cash)-2.477.63-0.524.643.78-0.59
Funds from Operations-4.98-4.60-6.96-10.36-13.09-9.22
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.461.67-1.69-0.963.40-5.53
Cash from Operating Activities-4.52-2.94-8.65-11.32-9.70-14.75
Capital Expenditures-0.06-0.04-0.01-0.10-0.02-0.01
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-70.1114.947.192.89-26.7818.59
Purchase of Investments-83.330.02-2.48-13.62-40.250.00
Sale Or Maturity of Investments13.2214.939.6716.5113.4718.59
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-70.1714.907.182.79-26.8018.58
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-1.46138.790.000.952.2028.53
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock-1.46138.790.000.952.2028.53
Proceedsfrom Stock Options-1.45138.660.000.501.1514.94
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-1.53138.70-0.090.852.0728.43
Exchange Rate Effect-0.412.320.35-0.16-2.09-1.83
Net Change in Cash-76.63152.99-1.20-7.85-36.5230.43
Free Cash Flow-4.58-2.98-8.66-11.43-9.71-14.76

Revenue breakdown

Pharmaceutical Preparations2024: 179.38K 2025: 33.08K
Germany2024: 179.38K 2025: 33.08K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3010.22%12.8M125.6M750.37K
2026-10-1510.13%12.7M125.6M755.87K
2026-09-309.84%12.4M125.6M848.25K
2026-09-159.64%12.1M125.6M1.05M
2026-08-319.79%12.3M125.6M1.16M
2026-08-147.53%9.5M125.6M1.17M
2026-07-317.26%9.3M128.5M1.81M
2026-07-156.91%8.9M128.5M2.05M
2026-06-306.32%8.1M128.5M1.96M
2026-06-155.41%7.0M128.5M1.74M
2026-05-295.33%6.8M128.5M1.59M
2026-05-1511.30%6.0M53.5M1.47M
2026-04-302.93%2.0M68.0M712.25K
2026-04-152.66%1.8M68.0M443.38K
2026-03-313.63%2.5M67.6M413.36K
2026-03-133.79%2.6M67.6M469.82K
2026-02-274.25%2.7M62.8M576.65K
2026-02-134.45%2.8M62.8M696.18K
2026-01-305.07%3.2M62.8M2.91M
2026-01-154.94%3.1M62.8M2.91M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.500.401.150.0026.4290.000.000.925-0.0080.000
call1.000.000.750.0010.8860.000.000.771-0.0060.001
call1.500.000.750.3112.6641010.000.806-0.0360.001
call2.000.000.500.009.6060.000.000.654-0.0370.001
call2.500.000.150.065.1421000.000.330-0.0190.001
call5.000.000.750.007.8080.000.000.281-0.0270.001
call7.500.000.750.008.9440.000.000.264-0.0300.001
put0.500.000.050.005.2600.000.00-0.072-0.0070.000
put1.000.000.050.001.8690.000.00-0.213-0.0060.001
put1.500.000.950.1010.4891.000.00-0.194-0.0360.001
put2.000.451.200.507.8850.000.00-0.346-0.0360.001
put2.500.951.700.008.9630.000.00-0.671-0.0200.001
put5.003.204.400.0013.9910.000.00-0.719-0.0270.001
put7.505.507.000.0016.7290.000.00-0.736-0.0300.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-06SEC
2026-11-036-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-03SEC
2026-11-036-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-03SEC
2026-10-226-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-22SEC
2026-08-17SCHEDULE 13GSEC
2026-08-14424B5SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13GSEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-12EFFECTEffectiveness filing by commission orderSEC
2026-08-06F-3Registration statement for specified transactions by certain foreign private issuersSEC
2026-08-06S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-06SEC
2026-08-06SCHEDULE 13GSEC
2026-06-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-05-14SCHEDULE 13GSEC
2026-05-12SCHEDULE 13GSEC
2026-05-076-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-07SEC
2026-05-07424B5SEC
2026-05-06424B5SEC
2026-05-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-06SEC
2026-05-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-31SEC
2026-05-046-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-04SEC
2026-04-286-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-28SEC
2026-04-236-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-23SEC
2026-04-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-09SEC
2026-04-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-02SEC
2026-03-2020-FRegistration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.2025-12-31SEC
2026-03-196-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-19SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
MONTANOVA CAPITAL, LLC15.57%
TCG Crossover Management, LLC9.84%
FMR LLC6.31%
Commodore Capital LP4.96%
Kalehua Capital Management LLC3.93%
Spruce Street Capital LP3.63%
683 Capital Management, LLC3.44%
FARALLON CAPITAL MANAGEMENT, L.L.C.2.26%
STEMPOINT CAPITAL LP2.19%
GREAT POINT PARTNERS LLC2.07%

Funds

Fund% owned
Fidelity Small Cap Growth Fund2.23%
Fidelity Advisor Biotechnology Fund2.17%
VANGUARD TOTAL INTERNATIONAL BOND II INDEX FUND2.10%
VANGUARD TOTAL INTERNATIONAL BOND INDEX FUND2.04%
Fidelity Small Cap Growth K6 Fund1.14%
Franklin Biotechnology Discovery Fund0.26%
Diversified Income Fund0.07%
Fidelity Nasdaq Composite Index Fund0.03%
TIFF MULTI-ASSET FUND0.02%
Blackstone Alternative Multi-Strategy Fund0.00%

OakChart. IFRX. Cached 15 minutes.

Some panels did not load: insider.